Inicio / Oncología / Abstracts de oncología / Safety and immunogenicity of…

Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

0 / 5 (0 votos)
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study

The Lancet Oncology

Fecha de publicación: 27 de abril de 2021

Autores: Leticia Monin, PhD *, Adam G Laing, PhD *, Miguel Muñoz-Ruiz, PhD *, Duncan R McKenzie, PhD *, Irene del Molino del Barrio, PhD *, Thanussuyah Alaguthurai, MSc *, Clara Domingo-Vila, BSc, Thomas S Hayday, PhD, Carl Graham, PhD, Jeffrey Seow, PhD, Sultan Abdul-Jawad, PhD, Shraddha Kamdar, PhD, Elizabeth Harvey-Jones, MBChB, Rosalind Graham, PhD, Jack Cooper, MBChB, Muhammad Khan, MRCP, Jennifer Vidler, MRCP, Helen Kakkassery, BSc, Shubhankar Sinha, BSc, Richard Davis, MSc, Liane Dupont, PhD, Isaac Francos Quijorna, PhD

DOI: https://doi.org/10.1016/S1470-2045(21)00213-8

Background: The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (Pfizer–BioNTech) vaccine in patients with cancer. Methods: For this prospective observational study, we recruited patients with cancer and healthy controls (mostly health-care workers) from three London hospitals between Dec 8, 2020, and Feb 18, 2021. Participants who were vaccinated between Dec 8 and Dec 29, 2020, received two 30 μg doses of BNT162b2 administered intramuscularly 21 days apart; patients vaccinated after this date received only one 30 μg dose with a planned follow-up boost at 12 weeks. Blood samples were taken before vaccination and at 3 weeks and 5 weeks after the first vaccination.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.